News

News Subscription

Apr 16. 2025
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Read more
Download
Apr 16. 2025
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
Read more
Download
Mar 14. 2025
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Read more
Download
Feb 18. 2025 / Ad hoc announcement
Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow
Read more
Download
Feb 05. 2025
Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea
Read more
Download
Jan 28. 2025
Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea
Read more
Download
Jan 08. 2025
Basilea provides portfolio update and outlook
Read more
Download
Dec 23. 2024 / Ad hoc announcement
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics
Read more
Download
Dec 16. 2024 / Ad hoc announcement
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
Read more
Download
Oct 10. 2024
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year
Read more
Download